BPS Bioscience, Inc.

Unique Portfolio of Proteins and Assay Kits for PD-1-related Research and Drug Discovery

BPS Bioscience, Inc. (“BPS”) announces the addition of a panel of 6 protease enzymes for identifying small molecule inhibitors of the Hepatitis C virus (HCV). These unique enzymes are also available for custom screening and profiling services.

Expanding the Largest Portfolio of Proteins and Assay Kits for Epigenetic Research and Drug Discovery

First commercially available NSD kits for inhibitor screening and profiling applications

Expanding the Array of Tools Available for Life Science Research

Announcing the Availability of Methyl-Lysine Reader Proteins and Assay Kits for a New Class of Epigenetic Drug...

BPS Bioscience, Inc. (“BPS”) announced the addition of 3 new assay kits (BRD9, CREBBP, and TRIM24) for identifying small molecule inhibitors of bromodomains (BRDs).

The Largest Selection of PARP Screening and Profiling Services now available: PARP’s 1, 2, 3, 5A (TNKS1), 5B (TNKS2), 6, 7, 8, 10, 11, 12 and 15.

Cell Lines now Available for Studying the Retinoic Acid Receptor (RAR), Notch, and Wnt Signaling Pathways

Largest Portfolio of Bromodomain Proteins and Assay Kits for a New Class of Epigenetic Drug Targets